Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

RORA: A novel candidate gene for autism regulates large number of other genes

A new study by Valerie Hu, Ph.D., professor of biochemistry and molecular medicine at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), reports that RORA, a novel candidate gene for autism discovered by her group in a 2010 study, regulates a large number of other genes associated with autism.

2 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

Tiny RNA molecules work as powerful regulators of immune response in mammals

A team led by scientists at The Scripps Research Institute (TSRI) has identified a family of tiny RNA molecules that work as powerful regulators of the immune response in mammals. Mice who lack these RNA molecules lose their normal infection-fighting ability, whereas mice that overproduce them develop a fatal autoimmune syndrome.

1 Jul 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

MorphoSys AG and Celgene Corporation today announced an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Researchers find elevated antibodies to gluten proteins of wheat in children with autism

Researchers have found elevated antibodies to gluten proteins of wheat in children with autism in comparison to those without autism. The results also indicated an association between the elevated antibodies and the presence of gastrointestinal symptoms in the affected children.

21 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

MMR booster does not result in worse JIA disease activity in children

Among children with juvenile idiopathic arthritis who had undergone primary immunization, the use of a measles-mumps-rubella booster compared with no booster did not result in worse JIA disease activity, according to a study in the June 19 issue of JAMA.

19 Jun 2013

Researchers identify new virus in patients with severe brain infections

Researchers have identified a new virus in patients with severe brain infections in Vietnam. Further research is needed to determine whether the virus is responsible for the symptoms of disease.

18 Jun 2013

Patients with central nervous system infections may suffer from the effects of CyCV-VN virus: Study

Patients in Vietnam and other locations with central nervous system infections may well be suffering from the effects of a newly discovered virus, according to a study to be published in mBio-, the online open-access journal of the American Society for Microbiology.

18 Jun 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

Antibody News and Research

Further Reading

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

RORA: A novel candidate gene for autism regulates large number of other genes

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

Tiny RNA molecules work as powerful regulators of immune response in mammals

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

Eisai submits BELVIQ NDS with Health Canada

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Researchers find elevated antibodies to gluten proteins of wheat in children with autism

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

MMR booster does not result in worse JIA disease activity in children

Researchers identify new virus in patients with severe brain infections

Patients with central nervous system infections may suffer from the effects of CyCV-VN virus: Study

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo